Pharmacopsychiatry 2024; 57(02): 78-81
DOI: 10.1055/a-2262-8297
Letter to the Editor

Risperidone-Induced Leukoneutropenia: Evidence from a Positive Rechallenge and Review of the Literature

1   Department of Pharmacovigilance, University of Sousse, Tunisia
,
Ahlem Ghanmi
2   Department of Psychiatry, Farhat Hachad Hospital, Sousse University, Tunisia
,
Soumaya Gazzeh
2   Department of Psychiatry, Farhat Hachad Hospital, Sousse University, Tunisia
,
Bochra Saguem
2   Department of Psychiatry, Farhat Hachad Hospital, Sousse University, Tunisia
,
Raoudha Slim
1   Department of Pharmacovigilance, University of Sousse, Tunisia
,
Jaafar Nakhli
2   Department of Psychiatry, Farhat Hachad Hospital, Sousse University, Tunisia
,
Chaker Ben Salem
1   Department of Pharmacovigilance, University of Sousse, Tunisia
› Institutsangaben
Preview

Antipsychotics can cause hematologic disorders, and they can have life-threatening consequences. Risperidone, less commonly associated with hematologic adverse effects, is an atypical antipsychotic medication used to treat conditions such as schizophrenia, bipolar disorder and irritability associated with autism. While risperidone primarily affects the central nervous system, it can have some hematologic adverse effects, although these are relatively rare. It is crucial to note that these side effects are not common, and most people taking risperidone do not experience hematologic disorders. The reporting of such disorders may be more frequent with clozapine compared to other atypical antipsychotics because clozapine treatment necessitates regular hematological monitoring [1].



Publikationsverlauf

Eingereicht: 07. Januar 2024
Eingereicht: 01. Februar 2024

Angenommen: 05. Februar 2024

Artikel online veröffentlicht:
12. März 2024

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany